SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has announced that the company CEO, Anthony Marucci, would be presenting at the 36th Annual Cowen and Company Healthcare Conference, due to be held on Tuesday, in Boston. The presentation would be focused on the corporate overview of the company. The presentation would also be archived, for 7-days, after the presentation on Celldex website. Added to this, the company had recently released its 4Q2015 results, to report a lower than expected loss.

Analysts at Zacks had expected Celldex to report an EPS of -$0.34, compared to the actual EPS of -$0.33. The figure was also 3-cents lower than that for the same period, during the preceding year. The quarter also experienced a 21.2% increase in revenues, on a year-over-year basis, to $1.8 million. The two main factors for this increase was the company’s recent collaboration, in clinical trials, with Bristol-Myers and an R&D agreement, with Rockfeller University. The company also experienced a 53% increase in full-year revenues.

The CEO of CLDX identified 2015 as a year of progress for Celldex and its product pipeline. He also pointed out that the company had successfully completed the phase-2 study of RINTEGA in recurrent GBM. The results of the study had pointed out a long-term overall survival benefit. However, analysts at TheStreet still believe that the stock is a sell. This is mainly due to the company’s weak operating cash flow and a deteriorating income. The details of the 4Q2015 also revealed higher expenses, related to commercial planning and personnel.

The analysts at Cantor Fitzgerald have downgraded the stock’s target price to $25, but maintained its buy rating. The view is mainly driven by the phase-2 study of RINTEGA, coming to an end. Added to this, the company’s product pipeline is broadening as well. Furthermore, Celldex has also announced that it would be initiating several new studies on RINTEGA, aimed at improving the drug.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) lost 0.73% during the March 4 session, to reach a close at $8.19.

SHARE
Previous articleOpko Health Inc. (NYSE:OPK)’s GeneDx Set to Present at 2016 ACMG Annual Meeting
Next articleJuno Therapeutics Inc (NASDAQ:JUNO) Receives Cash Boost from Alaska Based Fund
Steve Kanaval
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.